Author

R. Leiva

Universitat de Barcelona

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Molecular Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

J. Companys-Alemany· 2 shared B. D. Hammock· 1 shared C. Escolano· 1 shared C. Galdeano· 1 shared C. Grinyan-Ferre· 1 shared C. Morisseau· 1 shared C. Sanfeliu· 1 shared Christian Griñán‐FerréiD· 1 shared

Activity by Year

2019-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMolecular Biology

J. Companys-Alemany

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

RL-118 and 11β-HSD1 target engagement through TAPS assay: behaviour and molecular analysis

Dolors Puigoriol‐Illamola, J. Companys-Alemany, Natalie Z M Homer, R. Leiva, Santiago Vázquez, Damian J. Mole, Christian Griñán‐Ferré, Mercè Pallàs

This study investigates the effects of RL-118, an 11β-HSD1 inhibitor, on cognitive and molecular changes induced by chronic mild stress in SAMP8 mice, showing restoration of stress-induced impairments.

bioRxiv · Oct 27, 2020 · PreprintMolecular Biology

Pharmacological inhibition of soluble epoxide hydrolase as a new therapy for Alzheimer’s Disease

C. Grinyan-Ferre, S. Codony, E. Pujol, J. Yang, R. Leiva, C. Escolano, D. Puigoriol-Illamola, J. Companys-Alemany, R. Corpas, C. Sanfeliu, M. I. Loza, J. M. Brea, C. Morisseau, B. D. Hammock, S. Vazquez, , C. Galdeano

This study investigates the therapeutic potential of sEH inhibition in Alzheimer’s Disease, showing reduced cognitive impairment, tau pathology, and amyloid plaques in animal models.

bioRxiv · Apr 10, 2019Pharmacology & Toxicology